Arrys Therapeutics is advancing a first-in-class immuno-metabolism therapy involved with the prostaglandin E2 (PGE2) pathway.

Arrys Therapeutics

This highly selective antagonist ARY-007 targets the EP4 receptor which is associated with immunosuppression and tumor promotion through immune cell modulation.

ARY-007 has demonstrated favorable therapeutic characteristics in human clinical studies for non-oncology indications, and will be advanced in clinical oncology studies in collaboration with Arrys Therapeutics’ affiliate Kyn Therapeutics through an exclusive development agreement.

Contact us

Find us

Arrys Therapeutics
1030 Massachusetts Avenue
Suite 400
Cambridge, MA 02138

Call us